Mindray Announces Second Quarter 2013 Financial Results
Shenzhen, China – August 5, 2013 – Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2013.
Highlights for Second Quarter 2013
| • | Net revenues increased 14.7% year-over-year to $307.2 million. China sales were strong at $147.4 million, representing 27.9% year-over-year growth and 48.0% of the company’s total net revenues. |
| • | International sales were $159.7 million. Both the emerging markets and Western Europe recorded solid revenue performance with mid-teen year-over-year percentage growth. |
| • | In-vitro diagnostic sales grew 19.5% year-over-year. Reagent sales contributed 36.6% to the segment, up from 34.4% in the same period last year. |
| • | Non-GAAP operating income grew 15.2% to $73.1 million and non-GAAP net income increased 14.7% to $68.2 million. |
| • | Net operating cash flow for the quarter strengthened to $76.2 million, representing an increase of 24.3% from the same period last year, mainly as a result of improved working capital management. |
| • | The cash conversion cycle was 85 days, compared to 97 days in the same period last year, primarily due to better control on receivable collections. |
| • | In July, the company completed the acquisition of ZONARE, a U.S. high-end ultrasound technology provider. |
“In the second quarter, our strong China sales continued to drive our top-line performance and we are pleased that our sales in the emerging markets improved sequentially. Western Europe revenues remained solid despite the region’s economic weakness. Sales in North America were weak this quarter, primarily as a result of tough comparison over last year,” said Mr. Li Xiting, Mindray’s President and Co-Chief Executive Officer. “We further enhanced our efficiency with better management of our cash conversion cycle. We are also very excited about our recent acquisition of ZONARE, which greatly strengthened our ultrasound R&D capabilities and expanded our high-end product portfolio.”
SUMMARY – Second quarter 2013
(in $ millions, except per-share data) | Three Months Ended | |||||||||||
| June 30 | ||||||||||||
| 2013 | 2012 | % chg | ||||||||||
Net Revenues | 307.2 | 267.8 | 14.7 | % | ||||||||
Net Revenues Generated in China | 147.4 | 115.3 | 27.9 | % | ||||||||
Net Revenues Generated in International Markets | 159.7 | 152.5 | 4.7 | % | ||||||||
Gross Profit | 176.5 | 153.6 | 14.9 | % | ||||||||
Non-GAAP Gross Profit | 178.7 | 154.8 | 15.4 | % | ||||||||
Operating Income | 66.7 | 55.9 | 19.4 | % | ||||||||
Non-GAAP Operating Income | 73.1 | 63.5 | 15.2 | % | ||||||||
EBITDA | 78.9 | 66.4 | 18.8 | % | ||||||||
Net Income | 62.1 | 52.0 | 19.3 | % | ||||||||
Non-GAAP Net Income | 68.2 | 59.5 | 14.7 | % | ||||||||
Diluted EPS | 0.51 | 0.44 | 17.9 | % | ||||||||
Non-GAAP Diluted EPS | 0.56 | 0.50 | 13.4 | % | ||||||||
Net Revenues
Mindray reported net revenues of $307.2 million for the second quarter of 2013, a 14.7% increase from $267.8 million in the second quarter of 2012.
| • | Net revenues generated in China increased 27.9% to $147.4 million from $115.3 million in the second quarter of 2012. |
| • | Net revenues generated in the international markets increased 4.7% to $159.7 million from $152.5 million in the second quarter of 2012. |
Performance by Segment
Patient Monitoring & Life Support Products: Net revenues in this segment increased 2.3% to $117.2 million from $114.6 million in the second quarter of 2012, contributing 38.2% to total net revenues in the second quarter of 2013.
In-Vitro Diagnostic Products: Net revenues in this segment increased 19.5% to $88.3 million from $73.9 million in the second quarter of 2012, contributing 28.7% to total net revenues in the second quarter of 2013. Reagents sales represented 36.6% of this segment’s net revenues.
Medical Imaging Systems: Net revenues in this segment increased 18.6% to $76.1 million from $64.1 million in the second quarter of 2012, contributing 24.8% to total net revenues in the second quarter of 2013.
Others: Net revenues increased 68.7% to $25.5 million from $15.1 million in the second quarter of 2012, contributing 8.3% to total net revenues in the second quarter of 2013. Other net revenues mainly include sales from the orthopedics business, service revenues from extended warranties, sales of accessories and repair service revenues for post-warranty period.
Gross Margin
Second quarter 2013 gross profit was $176.5 million, a 14.9% increase from $153.6 million in the second quarter of 2012. Second quarter 2013 non-GAAP gross profit was $178.7 million, a 15.4% increase from $154.8 million in the second quarter of 2012. Second quarter 2013 gross margin was 57.5% compared to 57.4% both in the second quarter of 2012 and the first quarter of 2013. Non-GAAP gross margin was 58.2% compared to 57.8% in the second quarter of 2012 and 58.1% in the first quarter of 2013.
Operating Expenses
Selling expenses in the second quarter of 2013 were $54.6 million, or 17.8% of total net revenues, unchanged from the second quarter of 2012 but lower than the 19.5% in the first quarter of 2013. Non-GAAP selling expenses were $52.2 million, or 17.0% of total net revenues, unchanged from the second quarter of 2012 and lower than the 18.5% in the first quarter of 2013.
General and administrative expenses for the second quarter of 2013 were $26.6 million, or 8.7% of total net revenues, compared to 9.7% in the second quarter of 2012 and 11.0% in the first quarter of 2013. Non-GAAP general and administrative expenses for the second quarter of 2013 were $26.0 million, or 8.5% of total net revenues, compared to 8.7% in the second quarter of 2012 and 10.0% in the first quarter of 2013.
Research and development expenses for the second quarter of 2013 were $28.6 million, or 9.3% of total net revenues, compared to 8.9% in the second quarter of 2012 and 10.9% in the first quarter of 2013. Non-GAAP research and development expenses for the second quarter of 2013 were $27.4 million, or 8.9% of total net revenues, compared to 8.4% in the second quarter of 2012 and 10.5% in the first quarter of 2013.
Total share-based compensation expenses, which were allocated to cost of revenues and related operating expenses, were $3.2 million in the second quarter of 2013 compared to $6.0 million in the second quarter of 2012 and $4.8 million in the first quarter of 2013.
Operating income was $66.7 million in the second quarter of 2013, a 19.4% increase from $55.9 million in the second quarter of 2012. Non-GAAP operating income in the second quarter of 2013 was $73.1 million, a 15.2% increase from $63.5 million in the second quarter of 2012. Operating margin was 21.7% in the second quarter of 2013 compared to 20.9% in the second quarter of 2012 and 16.1% in the first quarter of 2013. Non-GAAP operating margin was 23.8% in the second quarter of 2013 compared to 23.7% in the second quarter of 2012 and 19.1% in the first quarter of 2013.
Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”)
Second quarter 2013 EBITDA increased 18.8% year-over-year to $78.9 million from $66.4 million in the second quarter of 2012.
Net Income
Net income increased 19.3% year-over-year to $62.1 million from $52.0 million in the second quarter of 2012. Non-GAAP net income increased 14.7% year-over-year to $68.2 million from $59.5 million in the second quarter of 2012. Net margin was 20.2% in the second quarter of 2013 compared to 19.4% in the second quarter of 2012 and 23.7% in the first quarter of 2013. Non-GAAP net margin was 22.2% in the second quarter of 2013, same with the second quarter of 2012 and compared to 26.7% in the first quarter of 2013.
Second quarter 2013 basic and diluted earnings per share were $0.52 and $0.51 respectively, compared to $0.45 and $0.44 in the second quarter of 2012. Basic and diluted non-GAAP earnings per share were $0.58 and $0.56 respectively, compared to $0.51 and $0.50 in the second quarter of 2012. Shares used in the computation of diluted earnings per share for the second quarter 2013 were 120.8 million.
Other Select Data
Accounts receivable turnover days were 52 days in the second quarter of 2013, improved from 64 days in the second quarter of 2012 and 66 days in the first quarter of 2013. Inventory turnover days were 88 days in the second quarter of 2013, compared to 87 days in the second quarter of 2012 and 103 days in the first quarter of 2013. Accounts payable turnover days were 54 days in the second quarter of 2013, the same with the second quarter of 2012 and compared to 59 days in the first quarter of 2013. Mindray calculates the above working capital turnover days using the average of the beginning and ending net balances of the quarter.
As of June 30, 2013, the company had $958.5 million in cash and cash equivalents as well as short-term investments, compared to $891.0 million as of March 31, 2013. Net cash generated by operating activities and net cash outflow for capital expenditures during the quarter were $76.2 million and $20.2 million respectively.
As of June 30, 2013, the company had around 7,540 employees.
Business Outlook for Full Year 2013
Mindray is raising its full year revenue guidance, expecting at least 18% growth over its full year 2012 net revenues.
The company maintains its full year 2013 non-GAAP net income guidance, expecting at least 15% growth over its non-GAAP net income for the full year of 2012. This guidance excludes any tax benefit related to the National Key Software Enterprise status and assumes a corporate income tax rate of 15% for the Shenzhen subsidiary.
The company expects its capital expenditure for full year 2013 to be around $130 million.
The company’s practice is to provide guidance on a full year basis only. This forecast reflects Mindray’s current and preliminary views, which are subject to change.
“Looking ahead, we expect China to continue to drive our overall growth and the emerging markets should gradually improve despite continued political and currency challenges in certain countries. As for the developed markets, while we are happy with our performance in Western Europe, we anticipate uncertainty to persist in our North American business,” commented Mr. Cheng Minghe, Mindray’s Co-Chief Executive Officer and Chief Strategic Officer. “Going forward, we will further enhance our efficiency to strengthen the company’s competitive position. On the M&A front, we are confident about the integration of ZONARE and will continue to seek other promising targets and partners.”
Conference Call Information
Mindray’s management will hold an earnings conference call at 8:00 AM on August 6, 2013 U.S. Eastern Time (8:00 PM on August 6, 2013 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows:
International Toll Free:
United States: +1-866-519-4004
Hong Kong: 800-930-346
China Landline: 800-819-0121
Local dial-in numbers:
United States: +1-845-675-0437
Hong Kong: +852-2475-0994
China Mobile: 400-620-8038
Passcode for all regions: Mindray
A replay of the conference call may be accessed by phone at the following numbers until August 21, 2013.
U.S. Toll Free: +1-855-452-5696
International: +1-646-254-3697
Passcode: 17658491
Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray’s website at: http://ir.mindray.com/.
Use of Non-GAAP Financial Measures
Mindray provides gross profit, selling expenses, general and administrative expenses, R&D expenses, operating income, net income and earnings per share on a non-GAAP basis that excludes share-based compensation expense and acquired intangible assets amortization expense, all net of related tax impact, as well as EBITDA to enable investors to better assess the company’s operating performance. The non-GAAP measures described by the company are reconciled to the corresponding GAAP measure in the exhibit below titled “Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures”.
The company has reported for the second quarter of 2013 and provided guidance for full year 2013 earnings on a non-GAAP basis. Each of the terms as used by the company is defined as follows:
| • | Non-GAAP gross profit represents gross profit reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets. |
| • | Non-GAAP operating income represents operating income reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets. |
| • | Non-GAAP selling expenses represent selling expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation, and amortization of acquired intangible assets. |
| • | Non-GAAP general and administrative expenses represent general and administrative expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation. |
| • | Non-GAAP research and development expenses represent research and development expenses reported in accordance with GAAP, adjusted for the effects of share-based compensation. |
| • | Non-GAAP net income represents net income reported in accordance with GAAP, adjusted for the effects of share-based compensation and amortization of acquired intangible assets, all net of related tax impact. |
| • | Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation. |
| • | EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization. |
The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three and six months ended June 30, 2012 and 2013, respectively, in the attached financial information.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray’s anticipated net revenues, non-GAAP net income and capital expenditure for 2013, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, the impact of our recent acquisition of Zonare, our expectation that China is to continue to drive our overall growth and the emerging markets should gradually improve despite continued political and currency challenges in certain countries, our anticipation of uncertainty to persist in our North American business, our optimism about the performance in Western Europe, that we will further enhance our efficiency to strengthen the company’s competitive position, that we are confident about the integration of ZONARE and that we will continue to seek other promising targets and partners on the M&A front, are forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors, including, without limitation, the growth and expected growth of the medical device market in China and internationally; relevant government policies and regulations relating to the medical device industry; market acceptance of our products; our expectations regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see “Risk Factors” beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 8, 2013. Our results of operations for the second quarter as of June 30, 2013 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.
All references to “shares” are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.
About Mindray
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China, we supply through our worldwide distribution network a broad range of products across three primary business segments, namely patient monitoring and life support, in-vitro diagnostic, and medical imaging systems. For more information, please visit http://ir.mindray.com.
For investor and media inquiries, please contact:
In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com
In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com
Exhibit 1
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands)
| As of December 31, 2012 | As of Jun 30, 2013 | |||||||
| US$ | US$ | |||||||
| (Note 1) | (unaudited) | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | 247,859 | 195,373 | ||||||
Restricted cash and restricted investment (Note 2) | 21,528 | 264 | ||||||
Short-term investments | 615,003 | 763,132 | ||||||
Accounts receivable, net | 185,701 | 183,219 | ||||||
Inventories | 110,099 | 128,150 | ||||||
Value added tax receivables | 7,427 | 19,351 | ||||||
Other receivables | 15,704 | 26,548 | ||||||
Prepayments and deposits | 11,081 | 14,745 | ||||||
Deferred tax assets,net | 6,443 | 8,106 | ||||||
|
|
|
| |||||
Total current assets | 1,220,845 | 1,338,888 | ||||||
Other assets | 10,811 | 10,844 | ||||||
Accounts receivables, net, non-current | 2,172 | 2,042 | ||||||
Advances for purchase of plant and equipment | 3,009 | 4,641 | ||||||
Property, plant and equipment, net | 268,010 | 285,727 | ||||||
Land use rights, net | 56,921 | 59,350 | ||||||
Intangible assets, net | 132,334 | 127,754 | ||||||
Goodwill | 163,016 | 170,063 | ||||||
|
|
|
| |||||
Total assets | 1,857,118 | 1,999,309 | ||||||
|
|
|
| |||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Short-term bank loans | 85,100 | 100,045 | ||||||
Notes payable | 8,697 | 7,983 | ||||||
Accounts payable | 53,244 | 74,992 | ||||||
Advances from customers | 17,550 | 22,581 | ||||||
Salaries payable | 69,919 | 53,313 | ||||||
Other payables | 108,528 | 113,804 | ||||||
Purchase consideration payable | 20,354 | 8,260 | ||||||
Income taxes payable | 30,305 | 18,199 | ||||||
Other taxes payable | 8,894 | 5,067 | ||||||
|
|
|
| |||||
Total current liabilities | 402,591 | 404,244 | ||||||
|
|
|
| |||||
Long-term bank loan | 50,039 | 95,013 | ||||||
Other long-term liabilities | 4,004 | 4,088 | ||||||
Deferred tax liabilities, net | 23,369 | 24,255 | ||||||
|
|
|
| |||||
Total liabilities | 480,003 | 527,600 | ||||||
Shareholders’ equity: | ||||||||
Ordinary shares | 15 | 15 | ||||||
Additional paid-in capital | 514,280 | 531,103 | ||||||
Retained earnings | 699,992 | 760,396 | ||||||
Accumulated other comprehensive income | 116,556 | 129,975 | ||||||
|
|
|
| |||||
Total shareholders’ equity | 1,330,843 | 1,421,489 | ||||||
Non-controlling interests | 46,272 | 50,220 | ||||||
|
|
|
| |||||
Total equity | 1,377,115 | 1,471,709 | ||||||
|
|
|
| |||||
Total liabilities and equity | 1,857,118 | 1,999,309 | ||||||
|
|
|
| |||||
| (1) | Financial information is extracted from the audited financial statements included in the Company’s fiscal year 2012 20F. |
| (2) | Restricted cash and restricted investment are mainly those purchase consideration in connection with our acquisition being held on escrow accounts. |
Exhibit 2
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except for share and per share data)
| Three months ended Jun 30, | Six months ended Jun 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| US$ | US$ | US$ | US$ | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
Net revenues | ||||||||||||||||
-PRC | 115,294 | 147,415 | 207,134 | 258,747 | ||||||||||||
- International | 152,536 | 159,736 | 279,713 | 290,507 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Net revenues | 267,830 | 307,151 | 486,847 | 549,254 | ||||||||||||
Cost of revenues | (114,208 | ) | (130,668 | ) | (212,900 | ) | (233,706 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Gross profit | 153,622 | 176,483 | 273,947 | 315,548 | ||||||||||||
Selling expenses | (47,759 | ) | (54,559 | ) | (87,488 | ) | (101,716 | ) | ||||||||
General and administrative expenses | (26,111 | ) | (26,629 | ) | (45,725 | ) | (53,213 | ) | ||||||||
Research and development expenses | (23,877 | ) | (28,573 | ) | (48,154 | ) | (54,901 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Income from operations | 55,875 | 66,722 | 92,580 | 105,718 | ||||||||||||
Other income, net | 388 | 421 | 973 | 499 | ||||||||||||
Interest income | 7,260 | 8,540 | 15,698 | 16,227 | ||||||||||||
Interest expense | (1,287 | ) | (1,471 | ) | (1,978 | ) | (2,443 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Income before income taxes and non-controlling interests | 62,236 | 74,212 | 107,273 | 120,001 | ||||||||||||
Provision for income taxes | (10,023 | ) | (10,743 | ) | (18,366 | ) | 2,191 | |||||||||
|
|
|
|
|
|
|
| |||||||||
Net income | 52,213 | 63,469 | 88,907 | 122,192 | ||||||||||||
Less: Net income attributable to non-controlling interests | (206 | ) | (1,419 | ) | (313 | ) | (2,718 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Net income attributable to the Company | 52,007 | 62,050 | 88,594 | 119,474 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Basic earnings per share | 0.45 | 0.52 | 0.76 | 1.01 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Diluted earnings per share | 0.44 | 0.51 | 0.74 | 0.99 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Shares used in the computation of: | ||||||||||||||||
Basic earnings per share | 116,547,129 | 118,519,629 | 116,283,063 | 118,350,730 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Diluted earnings per share | 119,394,768 | 120,779,113 | 119,353,032 | 120,909,507 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Exhibit 3
MINDRAY MEDICAL INTERNATIONAL LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
| Three months ended Jun 30, | Six months ended Jun 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| US$ | US$ | US$ | US$ | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
Cash flow from operating activities: | ||||||||||||||||
Net income | 52,213 | 63,469 | 88,907 | 122,192 | ||||||||||||
Adjustments to reconcile net income to net cash provided by operating activities | 21,872 | 17,019 | 36,280 | 32,329 | ||||||||||||
Changes in current assets and liabilities,net of effects of acquisitions | (12,731 | ) | (4,253 | ) | (3,711 | ) | (35,896 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Net cash provided by operating activities | 61,354 | 76,235 | 121,476 | 118,625 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Cash flow from investing activities: | ||||||||||||||||
Acquisition cost of subsidiaries, net of cash received | — | (13,646 | ) | (2,739 | ) | (17,485 | ) | |||||||||
Capital expenditure | (16,745 | ) | (20,198 | ) | (32,835 | ) | (40,240 | ) | ||||||||
Decrease in restricted cash and restricted investment | — | 15,865 | — | 21,264 | ||||||||||||
Proceeds from sale of short-term investments | — | 295,076 | 144,395 | 404,337 | ||||||||||||
Increase in short-term investments and changes in other investing activities | (32,637 | ) | (357,714 | ) | (125,489 | ) | (549,519 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Net cash used in investing activities | (49,382 | ) | (80,617 | ) | (16,668 | ) | (181,643 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
Cash flow from financing activities: | ||||||||||||||||
Repayment of bank loans | — | (35,000 | ) | — | (35,000 | ) | ||||||||||
Proceeds from bank loans | 2,000 | 35,000 | 52,000 | 95,000 | ||||||||||||
Dividend paid | — | — | (46,401 | ) | (59,070 | ) | ||||||||||
Proceeds from exercise of options | 4,691 | 2,098 | 14,138 | 8,852 | ||||||||||||
Cash contribution from non-controlling interest | — | — | 506 | — | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Net cash provided by financing activities | 6,691 | 2,098 | 20,243 | 9,782 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Net increase (decrease) in cash and cash equivalents | 18,663 | (2,284 | ) | 125,051 | (53,236 | ) | ||||||||||
Cash and cash equivalents, beginning of period | 231,010 | 195,744 | 124,311 | 247,859 | ||||||||||||
Effect of exchange rate changes on cash | (1,688 | ) | 1,913 | (1,377 | ) | 750 | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Cash and cash equivalents, end of period | 247,985 | 195,373 | 247,985 | 195,373 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Exhibit 4
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATIONS OF NON-GAAP RESULTS OF OPERATIONS MEASURES TO THE NEAREST COMPARABLE GAAP MEASURES
(Dollars in thousands, except for share and per share data)
| Three months ended Jun 30, | Six months ended Jun 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
| US$ | US$ | US$ | US$ | |||||||||||||
Non-GAAP net income attributable to the Company | 59,510 | 68,238 | 99,894 | 132,808 | ||||||||||||
Non-GAAP net margin | 22.2 | % | 22.2 | % | 20.5 | % | 24.2 | % | ||||||||
Amortization of acquired intangible assets | (1,629 | ) | (3,202 | ) | (3,264 | ) | (5,804 | ) | ||||||||
Deferred tax impact related to acquired intangible assets | 83 | 209 | 118 | 415 | ||||||||||||
Share-based compensation | (5,957 | ) | (3,195 | ) | (8,154 | ) | (7,945 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP net income attributable to the Company | 52,007 | 62,050 | 88,594 | 119,474 | ||||||||||||
GAAP net margin | 19.4 | % | 20.2 | % | 18.2 | % | 21.8 | % | ||||||||
Non-GAAP basic earnings per share | 0.51 | 0.58 | 0.86 | 1.12 | ||||||||||||
Non-GAAP diluted earnings per share | 0.50 | 0.56 | 0.84 | 1.10 | ||||||||||||
GAAP basic earnings per share | 0.45 | 0.52 | 0.76 | 1.01 | ||||||||||||
GAAP diluted earnings per share | 0.44 | 0.51 | 0.74 | 0.99 | ||||||||||||
Shares used in computation of: | ||||||||||||||||
Basic earnings per share | 116,547,129 | 118,519,629 | 116,283,063 | 118,350,730 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Diluted earnings per share | 119,394,768 | 120,779,113 | 119,353,032 | 120,909,507 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Non-GAAP operating income | 63,461 | 73,119 | 103,998 | 119,467 | ||||||||||||
Non-GAAP operating margin | 23.7 | % | 23.8 | % | 21.4 | % | 21.8 | % | ||||||||
Amortization of acquired intangible assets | (1,629 | ) | (3,202 | ) | (3,264 | ) | (5,804 | ) | ||||||||
Share-based compensation | (5,957 | ) | (3,195 | ) | (8,154 | ) | (7,945 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP operating income | 55,875 | 66,722 | 92,580 | 105,718 | ||||||||||||
GAAP operating margin | 20.9 | % | 21.7 | % | 19.0 | % | 19.2 | % | ||||||||
Non-GAAP gross profit | 154,796 | 178,705 | 276,245 | 319,419 | ||||||||||||
Non-GAAP gross margin | 57.8 | % | 58.2 | % | 56.7 | % | 58.2 | % | ||||||||
Amortization of acquired intangible assets | (960 | ) | (2,060 | ) | (1,926 | ) | (3,527 | ) | ||||||||
Share-based compensation | (214 | ) | (162 | ) | (372 | ) | (344 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP gross profit | 153,622 | 176,483 | 273,947 | 315,548 | ||||||||||||
GAAP gross margin | 57.4 | % | 57.5 | % | 56.3 | % | 57.5 | % | ||||||||
Non-GAAP selling expenses | (45,472 | ) | (52,191 | ) | (83,838 | ) | (97,097 | ) | ||||||||
Non-GAAP as % of total revenues | 17.0 | % | 17.0 | % | 17.2 | % | 17.7 | % | ||||||||
Amortization of acquired intangible assets | (669 | ) | (1,142 | ) | (1,338 | ) | (2,277 | ) | ||||||||
Share-based compensation | (1,618 | ) | (1,226 | ) | (2,312 | ) | (2,342 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP selling expenses | (47,759 | ) | (54,559 | ) | (87,488 | ) | (101,716 | ) | ||||||||
GAAP as % of total revenues | 17.8 | % | 17.8 | % | 18.0 | % | 18.5 | % | ||||||||
Non-GAAP general and administrative expenses | (23,317 | ) | (26,023 | ) | (42,418 | ) | (50,181 | ) | ||||||||
Non-GAAP as % of total revenues | 8.7 | % | 8.5 | % | 8.7 | % | 9.1 | % | ||||||||
Share-based compensation | (2,794 | ) | (606 | ) | (3,307 | ) | (3,032 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP general and administrative expenses | (26,111 | ) | (26,629 | ) | (45,725 | ) | (53,213 | ) | ||||||||
GAAP as % of total revenues | 9.7 | % | 8.7 | % | 9.4 | % | 9.7 | % | ||||||||
Non-GAAP research and development expenses | (22,546 | ) | (27,372 | ) | (45,991 | ) | (52,674 | ) | ||||||||
Non-GAAP as % of total revenues | 8.4 | % | 8.9 | % | 9.4 | % | 9.6 | % | ||||||||
Share-based compensation | (1,331 | ) | (1,201 | ) | (2,163 | ) | (2,227 | ) | ||||||||
|
|
|
|
|
|
|
| |||||||||
GAAP research and development expenses | (23,877 | ) | (28,573 | ) | (48,154 | ) | (54,901 | ) | ||||||||
GAAP as % of total revenues | 8.9 | % | 9.3 | % | 9.9 | % | 10.0 | % | ||||||||
Exhibit 5
MINDRAY MEDICAL INTERNATIONAL LIMITED
RECONCILIATION OF GAAP NET INCOME TO EARNINGS BEFORE INTEREST, TAXES, DEPRECIATION AND AMORTIZATION
(Dollars in thousands)
| Three months ended Jun 30, | Six months ended Jun 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| US$ | US$ | US$ | US$ | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
GAAP net income attributable to the Company | 52,007 | 62,050 | 88,594 | 119,474 | ||||||||||||
Interest income | (7,260 | ) | (8,540 | ) | (15,698 | ) | (16,227 | ) | ||||||||
Interest expense | 1,287 | 1,471 | 1,978 | 2,443 | ||||||||||||
Provision for income taxes | 10,023 | 10,743 | 18,366 | (2,191 | ) | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Earnings before interest and taxes (“EBIT”) | 56,057 | 65,724 | 93,240 | 103,499 | ||||||||||||
Depreciation | 7,451 | 7,934 | 14,041 | 15,710 | ||||||||||||
Amortization | 2,903 | 5,220 | 5,792 | 9,497 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
Earnings before interest, taxes, depreciation, and amortization (“EBITDA”) | 66,411 | 78,878 | 113,073 | 128,706 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||